DPhil research opportunity
MA; MBBS; MRCP; FRCPath; PhD
Cancer Research UK Advanced Clinician Scientist
Using single-cell approaches to study normal and malignant megakaryocyte development and myeloproliferative neoplasms
I study megakaryocytes - large, rare cells found in the bone marrow that release blood platelets into the circulation and also produce many growth factors and other proteins that regulate blood cell development and the bone marrow microenvironment. My group applies state-of-the-art single-cell approaches to clarify the cellular pathways by which megakaryocytes arise from haematopoietic stem cells. This is important as in certain malignancies, such as erythro-megakaryocytic leukaemias and myeloproliferative neoplasms, megakaryocytes develop abnormally and contribute to key pathological features of the disease, including the harmful scarring that destroys the bone marrow.
I trained at Clare College, Cambridge, Imperial College London/The Hammersmith Hospital, Cornell, New York, and the National Institutes of Health, Bethesda USA and am currently a Cancer Research UK Advanced Clinician Scientist and Honorary Consultant in Haematology, Oxford University Hospitals NHS Trust. I am also a Senior Fellow of New College, Oxford.
Psaila B. et al, (2020), Mol Cell, 78, 477 - 492.e8
Thaventhiran JED. et al, (2020), Nature
Disease progression in patients with essential thrombocythaemia receiving anagrelide within a single institution
Gray N. et al, (2020), BRITISH JOURNAL OF HAEMATOLOGY, 189, 76 - 77
Hua P. et al, (2019), Blood, 134, 2111 - 2115
Brierley CK. and Psaila B., (2019), Blood, 134, 1778 - 1780